Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 1
1947 1
1948 1
1949 1
1950 2
1951 3
1952 2
1954 4
1955 4
1956 7
1957 3
1958 2
1959 2
1960 2
1961 1
1962 3
1963 2
1964 6
1965 9
1966 10
1967 15
1968 15
1969 12
1970 23
1971 22
1972 32
1973 32
1974 26
1975 36
1976 19
1977 24
1978 33
1979 16
1980 34
1981 29
1982 30
1983 34
1984 45
1985 41
1986 40
1987 39
1988 52
1989 57
1990 67
1991 50
1992 47
1993 51
1994 58
1995 43
1996 52
1997 53
1998 52
1999 62
2000 70
2001 62
2002 80
2003 73
2004 69
2005 80
2006 91
2007 76
2008 77
2009 68
2010 70
2011 74
2012 97
2013 90
2014 104
2015 132
2016 116
2017 99
2018 115
2019 102
2020 112
2021 107
2022 122
2023 109
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

3,271 results

Results by year

Filters applied: . Clear all
Page 1
Lymphoma: Diagnosis and Treatment.
Lewis WD, Lilly S, Jones KL. Lewis WD, et al. Am Fam Physician. 2020 Jan 1;101(1):34-41. Am Fam Physician. 2020. PMID: 31894937 Free article. Review.
It is traditionally classified broadly as non-Hodgkin or Hodgkin lymphoma. Approximately 82,000 new U.S. patients are diagnosed with lymphoma annually. ...Chemotherapy treatment plans differ between the main subtypes of lymphoma. Non-Hodgkin …
It is traditionally classified broadly as non-Hodgkin or Hodgkin lymphoma. Approximately 82,000 new U.S. patients are d …
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2022 Nov;97(11):1478-1488. doi: 10.1002/ajh.26717. Epub 2022 Sep 19. Am J Hematol. 2022. PMID: 36215668 Free article.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States. ...RISK-ADAPTED THERAPY: Initial therapy for HL pati …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually …
Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM. Ansell SM. Mayo Clin Proc. 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. Mayo Clin Proc. 2015. PMID: 26541251 Review.
This disease represents approximately 11% of all lymphomas seen in the United States and comprises 2 discrete disease entities--classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Within the subcategorization o …
This disease represents approximately 11% of all lymphomas seen in the United States and comprises 2 discrete disease entities …
Revised response criteria for malignant lymphoma.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Cheson BD, et al. J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22. J Clin Oncol. 2007. PMID: 17242396
RESULTS: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. CONCLUSION: We hope that these guidelines will be adopte …
RESULTS: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and …
Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2020 Aug;95(8):978-989. doi: 10.1002/ajh.25856. Epub 2020 Jun 8. Am J Hematol. 2020. PMID: 32384177 Free article.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8480 new patients annually and representing approximately 10% of all lymphomas in the United States. DIAGNOSIS: Hodgkin lymphoma is composed of two disti …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8480 new patients annually …
Consensus recommendations on the management of toxicity associated with CD3CD20 bispecific antibody therapy.
Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, Thieblemont C, Ursu R, Bartlett N, Nachar V, Weiss J, Osterson J, Patel K, Brody J, Abramson JS, Lunning M, Shah NN, Ayed A, Kamdar M, Parsons B, Caimi P, Flinn I, Herrera A, Sharman J, McKenna M, Armand P, Kahl B, Smith S, Zelenetz A, Budde LE, Hutchings M, Phillips T, Dickinson M. Crombie JL, et al. Blood. 2024 Apr 18;143(16):1565-1575. doi: 10.1182/blood.2023022432. Blood. 2024. PMID: 38252906
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have demonstrated remarkable single-agent activity in patients with heavily pretreated disease, and 3 dr …
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin …
Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Olsen EA, et al. J Clin Oncol. 2011 Jun 20;29(18):2598-607. doi: 10.1200/JCO.2010.32.0630. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576639 Free PMC article.
Mycosis fungoides (MF) and Sezary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. ...This article presents consensus recommendations for the general conduct o …
Mycosis fungoides (MF) and Sezary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that disti …
Hodgkin's lymphoma: 2023 update on treatment.
Zhang S, Liu X, Li L, Qiu L, Qian Z, Zhou S, Wang X, Zhang H. Zhang S, et al. Cancer Biol Med. 2023 Dec 29;21(4):269-73. doi: 10.20892/j.issn.2095-3941.2023.0427. Cancer Biol Med. 2023. PMID: 38164723 Free PMC article. No abstract available.
3,271 results